Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib
- Beuselinck, Benoit
- Medioni, J
- Wolter, Pascal
- Blesius, A
- Karadimou, A
- Schöffski, Patrick
- Escudier, B J
- Zucman-Rossi, J
- Paridaens, Robert
- Oudard, S
Publication date
March 2011
DOI Publisher
Grune & Stratton ISSN
0732-183X Journal
0732-183x Citation count (estimate)
4Abstract
388 Background: With a median progression-free survival(PFS) of 8.2 months (mo) (vs. 19.1 mo; p<0.0001) and overall survival (OS) of 19.5 mo (vs. 38.5 mo; p<0.0001), metastatic renal cell carcinoma (m-RCC) patients (pts) with bone metastases (BM) have a poorer outcome under sunitinib (SUN) than pts without BM (Beuselinck et al, Annals of Oncology 2010). The aim of this retrospective study was to determine additional prognostic factors in this poor risk subgroup of pts.status: publishe
Add to ORKG